Seagen

This biopharma company has marked out a path to profitability by licensing its drug expertise and antibody platforms to partners such as Pfizer.

HBM gets health boost from drug licensing deals

The biopharma company has marked out a path to profitability by licensing its drug expertise and antibody platforms to partners such as Pfizer Key Takeaways: Nona Biosciences, a subsidiary of…
2142.HK

Recent Articles

RELATED ARTICLES

  1. WuXi Biologics is spinning off its WuXi XDC ADS unit
    WuXi Biologics hatches new baby with ADC drug unit IPO
    2269.HK
  2. Akeso marks profit milestone with swift rights issue
    9926.HK
  3. InSilico seeks IPO boost to get AI drugs over the line
  4. AstraZeneca pays hefty price for Chinese weight-loss drug
    AZN.US
  5. RemeGen hopes for pain relief from expanded drug uses
    9995.HK 688331.SHG
  6. Everest reaches new heights on growing drug sales
    1952.HK
  7. CStone breaks up with drugs partner as U.S. rollout stalls
    2616.HK
Discover hidden China stock gems in our weekly newsletter

Follow us

Facebook Twitter Linkedin Weixin Weibo File-alt

Subscribe to Our Free eNewsletter

Subscribe

Check out our content with some of our syndication partners